Explore

Trendline Trendline
Eli Lilly Showcases Weight Loss Drug Benefits at American Diabetes Association Meeting

Eli Lilly Showcases Weight Loss Drug Benefits at American Diabetes Association Meeting

Eli Lilly Showcases Weight Loss Drug Benefits at American Diabetes Association Meeting
Trendline Trendline
OrsoBio to Present New Data on Mitochondrial Protonophore at ADA 2026, Highlighting Potential Benefits for Obesity Treatment

OrsoBio to Present New Data on Mitochondrial Protonophore at ADA 2026, Highlighting Potential Benefits for Obesity Treatment

OrsoBio to Present New Data on Mitochondrial Protonophore at ADA 2026, Highlighting Potential Benefits for Obesity Treatment
Trendline Trendline
Ascletis Pharma Showcases Promising Obesity Treatments at ADA 2026

Ascletis Pharma Showcases Promising Obesity Treatments at ADA 2026

Ascletis Pharma Showcases Promising Obesity Treatments at ADA 2026
Trendline Trendline
Ascletis Showcases Obesity Treatment Advancements at ADA 2026 Scientific Sessions

Ascletis Showcases Obesity Treatment Advancements at ADA 2026 Scientific Sessions

Ascletis Showcases Obesity Treatment Advancements at ADA 2026 Scientific Sessions
Trendline Trendline
Ambrosia Biosciences Reveals Promising Preclinical Data for Obesity Treatment Candidate AMB-702

Ambrosia Biosciences Reveals Promising Preclinical Data for Obesity Treatment Candidate AMB-702

Ambrosia Biosciences Reveals Promising Preclinical Data for Obesity Treatment Candidate AMB-702
Trendline Trendline
Ambrosia Biosciences Reveals Promising Preclinical Data for Obesity Drug Candidate AMB-702

Ambrosia Biosciences Reveals Promising Preclinical Data for Obesity Drug Candidate AMB-702

Ambrosia Biosciences Reveals Promising Preclinical Data for Obesity Drug Candidate AMB-702
Trendline Trendline
Ascletis Pharma Showcases Obesity Treatment Innovations at ADA 2026

Ascletis Pharma Showcases Obesity Treatment Innovations at ADA 2026

Ascletis Pharma Showcases Obesity Treatment Innovations at ADA 2026
Trendline Trendline
Structure Therapeutics Reports Positive Phase 2b Results for Obesity Drug Aleniglipron

Structure Therapeutics Reports Positive Phase 2b Results for Obesity Drug Aleniglipron

Structure Therapeutics Reports Positive Phase 2b Results for Obesity Drug Aleniglipron
Trendline Trendline
Structure Therapeutics Publishes Phase 2b Trial Results of Aleniglipron for Obesity in Nature Medicine

Structure Therapeutics Publishes Phase 2b Trial Results of Aleniglipron for Obesity in Nature Medicine

Structure Therapeutics Publishes Phase 2b Trial Results of Aleniglipron for Obesity in Nature Medicine
Trendline Trendline
Roche and Zealand Pharma's Amylin Analog Petrelintide Shows Moderate Weight Loss in Phase 2 Study

Roche and Zealand Pharma's Amylin Analog Petrelintide Shows Moderate Weight Loss in Phase 2 Study

Roche and Zealand Pharma's Amylin Analog Petrelintide Shows Moderate Weight Loss in Phase 2 Study
Trendline Trendline
Novo Nordisk CEO Confident in CagriSema's Market Impact Amid Obesity Drug Competition

Novo Nordisk CEO Confident in CagriSema's Market Impact Amid Obesity Drug Competition

Novo Nordisk CEO Confident in CagriSema's Market Impact Amid Obesity Drug Competition
Trendline Trendline
Structure Therapeutics' Obesity Drug Aleniglipron Shows Promising Weight Loss Results in Phase 2b Trial

Structure Therapeutics' Obesity Drug Aleniglipron Shows Promising Weight Loss Results in Phase 2b Trial

Structure Therapeutics' Obesity Drug Aleniglipron Shows Promising Weight Loss Results in Phase 2b Trial